Dr. Hönle (HNL) Q1 2026 earnings summary

Executive summary

• Revenue remained stable at €21.5 million, up 0.3% year-over-year, with gross profit rising 0.9% to €14.4 million.

• EBITDA dropped 48.7% to €0.5 million, and EBIT fell to -€0.8 million, reflecting higher operating expenses and exchange rate impacts.

• Net loss widened to -€1.5 million from -€0.6 million year-over-year; EPS declined to -€0.25.

Financial highlights

• Operating cash flow turned positive at €0.2 million, up from -€0.6 million last year.

• Cash and cash equivalents decreased by €1.0 million to €6.7 million during the quarter.

• Equity ratio improved slightly to 53.3%.

• Total assets declined by 2.4% to €142.0 million.

Outlook and guidance

• Management expects FY 2025/26 revenue between €95–105 million, assuming stable macro conditions.

• EBITDA forecasted at €6–9 million, with the lower end reflecting subdued demand.

• Guidance assumes no major geopolitical escalation and successful internal efficiency measures.